Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310229 | 0.89 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL3308151 | 0.89 | HTT (0.40) | ALDH1A1 | |
| SCHEMBL3308142 | 0.78 | HTT (0.39) | ALDH1A1 | |
| SCHEMBL3279154 | 0.76 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL3273615 | 0.72 | LMNA (0.39) | ALDH1A1 | |
| SCHEMBL10103045 | 0.72 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL3309734 | 0.71 | KDM4E (0.40) | ALDH1A1 | |
| SCHEMBL3279143 | 0.70 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL3273645 | 0.62 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL798617 | 0.61 | PIK3CG (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8207349-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100113414-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| EP-2148870-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008130584-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR17 | ALDH1A1 748/4885 |
| US-20100113414-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | MKI67, CYP11B1, IGF1R | ALDH1A1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.